A real-world study found evolocumab cut fatal or nonfatal heart attack risk 20% vs ezetimibe in adults with ASCVD and prior statin use.
|Articles|June 9, 2022
Bio-Rad Launches SEQuoia Express Stranded RNA Library Prep Kit
Author(s)BioPharm International Editors
Bio-Rad’s SEQuoia Express Stranded RNA Library Prep Kit is designed to construct efficient RNA sequencing workflows.
Advertisement
Bio-Rad announced the launch of the SEQuoia Express Stranded RNA Library Prep Kit on June 6, 2022. The kit is designed to construct robust libraries for efficient RNA sequencing (RNA-Seq) workflows in comprehensive transcriptome profiling.
According to a company press release, the SEQuoia is a three-tube kit that uses a novel reverse transcriptase and a ligation-free adaptor addition chemistry to produce a reproducible, quantitative RNA-Seq library in three hours. The kit allows researchers to construct robust libraries that capture messenger RNA and long noncoding RNA (> 200 binding proteins) transcripts for differential gene expression analysis and novel transcript delivery.
“Current RNA library preparation approaches are time-consuming, complex, and potentially error-prone, with sample loss observed at each stage in processes with multiple steps,” said Simon May, executive vice-president and president, Life Science Group, Bio-Rad, in the press release. “Bio-Rad offers scientists an enhanced solution, combining its rapid NGS [next generation sequencing] library preparation with integrated data analysis to overcome these difficulties and enable the widespread adoption of RNA-based sequencing."
Source: Bio-Rad
Advertisement
Related to this article
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Johnson & Johnson's amivantamab (Rybrevant Faspro) won accelerated FDA approval for pretreated recurrent head and neck cancer.
Oxford spinout Alethio Therapeutics closed a $90 million Series A to take ATX-011, a monoclonal antibody against the G6B receptor, into Phase 1/2a studies in essential thrombocythemia. It is also developing a G6B-targeted ADC for myelofibrosis.
T-Therapeutics closed an oversubscribed $133 million Series B backed by Eli Lilly, JJDC, and others. The funding will take its first T-cell receptor bispecifics in cancer and autoimmune disease into clinical trials.
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
FDA’s draft framework would let sponsors add patient-specific genome editing variants to an approved BLA using in vitro data. Here is what the guidance proposes, what evidence it asks for, and what remains unresolved.
Healthy-volunteer data show sustained TL1A suppression and a profile supporting infrequent subcutaneous dosing. Caldera also licensed a second bispecific, targeting IL-17 and TL1A, from Qyuns Therapeutics.
Advertisement
Advertisement
Trending on BioPharm International
1
Spyre’s Anti-TL1A Antibody SPY072 Misses in Psoriatic Arthritis and Axial Spondyloarthritis, Shifts Focus to Hidradenitis Suppurativa
2
T-Therapeutics Raises $133 Million to Take TCR Bispecifics Into the Clinic
3
Boehringer Ingelheim Licenses Six Preclinical ADC and T-Cell Engager Programs From SBP Group in Deal Worth Up to $7 Billion
4
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
5